AURA: Aura Biosciences Inc Company Value to Net Income

Aura Biosciences Inc - graphic logo of issuer AURA

Aura Biosciences, Inc. (AURA) is developing an innovative targeted therapy for ocular tumors backed by a robust patent portfolio, and the company's price action at the value of -5.40 is illustrated below. The business relies on global reach through oncology centers, thereby minimizing marketing expenses. The stability of clinical trials is ensured by strict control over the supply of rare components and the diversification of logistics chains.

Price to Earnings Ratio: Aura Biosciences, Inc. (AURA) for 08/14/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for Aura Biosciences Inc (AURA)

- share price and expert price forecast:
Summary company analysis:AURA, Aura Bio
Flagship merchandise of Aura Biosciences

Long-term investing requires strict control over market premiums relative to a business's actual profits. The stability of Aura Biosciences, Inc. (AURA) is supported by the humanitarian status of biomedicine, which minimizes geopolitical risks during valuation. The company's fundamental P/E multiple compares the current share price to net income, measuring the market's willingness to pay for future growth. Low indicator values signal undervaluation, although they may indicate issues with cash flow generation.

Competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV